

Managing acute myocardial infarction: are we ready for new advances?

Poh K K

In this issue of the Singapore Medical Journal, four articles are published on acute myocardial infarction (AMI). Jim et al described predictors of inhospital outcome after a first inferior AMI;⁽¹⁾ Biswas et al reviewed a relatively new imaging technology for prognostication and risk stratification in patients with AMI;⁽²⁾ Wei et al discussed the potential use of human stem cells for post-MI cardiac repair;⁽³⁾ and Norasyikin et al investigated the prevalence of adrenal insufficiency in a small series of patients admitted with acute coronary syndrome.⁽⁴⁾

Ischaemic heart disease is today a major contributor of morbidity and mortality in Singapore and also worldwide.^(5,6) In Singapore, it accounted for 18% of the total deaths in 2005. AMI, which reflects one end of a spectrum of the manifestations of coronary artery disease, is associated with significant mortality.⁽⁷⁾ In addition, those who survive the infarction may face sequelae such as heart failure, recurrent major adverse cardiac events, physical functional decline and a long-lasting psychological burden. The clinical presentation of AMI itself is also highly variable. On one hand, it may be completely asymptomatic – the so-called “silent MI”. On the other hand, it may manifest as chest pain or sudden cardiac death. For patients who present for medical treatment, early diagnosis and appropriate management of the AMI are both critical for a successful outcome.

The prognostic parameters upon hospital admission for patients presenting with ST-elevation MI (STEMI) include the following: basic demographics (outcome is poorer with increasing age and the female gender), presence of cardiogenic shock or heart failure and the size of the MI (which may be assessed from electrocardiography [ECG] changes and peak cardiac enzyme levels). Jim et al found that in patients presenting with a first inferior wall STEMI in the thrombolytic era, advanced age, female gender, lateral wall extension (diagnosed by ECG), complete atrioventricular and bundle branch block, absence of thrombolytic therapy and cardiac free wall rupture were all associated with a higher inhospital mortality.⁽¹⁾ These findings are actually not surprising, but they serve to remind us of the importance of identifying patients with higher risk profiles. Furthermore, in the modern era of AMI management, clinical outcomes of STEMI will depend

critically on the reperfusion time, i.e. the time interval between the onset of symptoms and the implementation of reperfusion therapy, which is either thrombolytic therapy or coronary angioplasty intervention.⁽⁸⁾ The door-to-needle time for thrombolytic therapy or the door-to-balloon time for primary percutaneous coronary intervention is an important parameter which should be monitored and reduced as much as possible.^(9,10) In addition, the time interval time between symptom onset to arrival at the emergency department is also very important and should be as short as possible. Finally, the choice of ancillary and medical therapies also affects the clinical outcomes.^(11,12)

In the post-AMI phase, transthoracic echocardiography is usually performed to assess the left ventricular (LV) function and to detect any resultant complication.⁽¹³⁾ Both systolic and diastolic dysfunctions have prognostic significance.⁽¹⁴⁾ The presence of a LV thrombus in the setting of poor LV systolic function detected by echocardiography will require anticoagulation therapy, unless it is contraindicated. Exercise stress tests for risk stratification should be routinely considered.⁽¹¹⁾ In many cases, an invasive strategy with coronary angiography will also be adopted. This test directly assesses the culprit coronary artery and, where appropriate, may lead to percutaneous coronary intervention of the infarct-related lesion. Biswas et al published an article on BMIPP imaging, using fatty acid metabolism as a means of detecting ischaemic and viable myocardium.⁽²⁾ Currently, in addition to single-photon emission computed tomography,⁽¹⁵⁾ cardiac magnetic resonance studies can also aid in prognostication.⁽¹⁶⁾ Whether these newer technologies will become routine investigations in the management of post-MI patients remain to be seen. Not only will these new tests need to show incremental benefit, but they should also ideally not be too technically difficult to perform (with relatively rapid throughput) and not too costly. The accompanying risks including nuclear activity/radiation exposure should also not be too high.

The promise of new imaging modalities is that they are able to identify patients who may benefit from new therapies.⁽⁵⁾ Though reperfusion therapy has been a milestone in the treatment of AMI and has significantly improved survival and prognosis,⁽¹⁾ the development

Cardiac
Department,
National University
Heart Centre
Singapore,
Yong Loo Lin
School of Medicine,
National University
of Singapore,
5 Lower Kent
Ridge Road,
Singapore 119074

Poh KK, FRCP,
FACC, FAMS
Associate Professor
and Consultant

Correspondence to:
Dr Poh Kian Keong
Tel: (65) 9237 3289
Fax: (65) 6872 2998
Email: mdcpkk@nus.
edu.sg

of heart failure, particularly in those with a sizable myocardial damage, remains a major challenge. Cell therapy may provide a novel therapeutic option to modify LV remodelling processes and prevent post-infarction heart failure. Over the last decade, a myriad of cell types have been tested experimentally, leading to a flurry of early uncontrolled and small-sized clinical trials. Wei et al reviewed some of the existing evidence on the beneficial effect of this promising therapy as well as the current limitations, mechanistic uncertainties and controversies.⁽³⁾ It is possible that the next decade will see cell therapy be utilised as adjuvant therapeutic agents in AMI. While we need to proceed with cautious optimism, safety should always be top in our priority.

Currently, we are already doing better in reducing AMI mortality compared to the past.⁽¹⁷⁾ As we optimise our management strategies for AMI, there is continuing research and advances in this field. This will undoubtedly result in a better understanding of the biology of the atherosclerotic plaque in the coronary artery as well as better imaging modalities and better novel therapeutic agents for the treatment of AMI and its complications.

REFERENCES

1. Jim MH, Chan AO, Tse HF, Lau CP. Predictors of in-hospital outcome after acute inferior wall myocardial infarction. *Singapore Med J* 2009; 50: 956-61.
2. Biswas SK, Sarai M, Hishida H, Ozaki Y. 123I-BMIPP fatty acid analogue imaging is a novel diagnostic and prognostic approach following acute myocardial infarction. *Singapore Med J* 2009; 50: 943-8.
3. Wei HM, Wong P, Hsu LF, Shim W. Human bone marrow-derived adult stem cells for post-myocardial infarction cardiac repair: current status and future directions. *Singapore Med J* 2009; 50: 935-42.
4. Norasyikin AW, Norlela S, Rozita M, et al. Adrenal insufficiency in acute coronary syndrome. *Singapore Med J* 2009; 50: 962-6.
5. Poh KK. Gene and cell therapy for chronic ischaemic heart disease. *Expert Opin Biol Ther* 2007; 7:5-15.
6. Mak KH, Chia KS, Kark JD, et al. Ethnic differences in acute myocardial infarction in Singapore. *Eur Heart J* 2003; 24:151-60.
7. Chia BL. Experience in the treatment of acute myocardial infarction in a coronary care unit. *Singapore Med J* 1979; 20:417-23.
8. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. *Circulation* 2004; 109:1223-5.
9. Lee CH, Ooi SB, Tay EL, et al. Shortening of median door-to-balloon time in primary percutaneous coronary intervention in Singapore by simple and inexpensive operational measures: clinical practice improvement program. *J Interv Cardiol* 2008; 21:414-23.
10. Rathore SS, Curtis JP, Chen J, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. *BMJ* 2009; 338:b1807.
11. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). *Circulation* 2004;110:588-636.
12. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2008; 51:210-47.
13. Chaitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). *J Am Soc Echocardiogr* 2003; 16:1091-110.
14. Khumri TM, Reid KJ, Kosiborod M, Spertus JA, Main ML. Usefulness of left ventricular diastolic dysfunction as a predictor of one-year rehospitalization in survivors of acute myocardial infarction. *Am J Cardiol* 2009; 103:17-21.
15. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction. *Circulation* 2000; 101:101-8.
16. Kwong RY, Korlakunta H. Diagnostic and prognostic value of cardiac magnetic resonance imaging in assessing myocardial viability. *Top Magn Reson Imaging* 2008; 19:15-24.
17. Krumholz HM, Wang Y, Chen J, et al. Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. *JAMA* 2009; 302:767-73.